C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg
Standard
C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. / Ganschow, Rainer; Richter, A; Grabhorn, Enke; Schulz, A; von Hugo, A; Mir, Thomas; Broering, D C; Rogiers, X; Hinrichs, B; Burdelski, M.
in: PEDIATR TRANSPLANT, Jahrgang 8, Nr. 2, 2, 04.2004, S. 185-188.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg
AU - Ganschow, Rainer
AU - Richter, A
AU - Grabhorn, Enke
AU - Schulz, A
AU - von Hugo, A
AU - Mir, Thomas
AU - Broering, D C
AU - Rogiers, X
AU - Hinrichs, B
AU - Burdelski, M
PY - 2004/4
Y1 - 2004/4
N2 - Pharmacokinetic studies in adult and pediatric liver transplant recipients have shown that the C(2) monitoring is superior to the traditional determination of CsA trough levels (C(0)) as an estimate of CsA exposure. However, target reference values for C(2) in very small infants have not been established yet. The objective of our study was to assess the distribution of C(2) levels in the first week following Ltx and to analyze enteral absorption of CsA for this group of patients. We documented CsA C(0) and C(2) levels in 25 infants with a body weight below 10 kg (median 6.8 kg; range 3.0-9.8 kg) in the first 7 days after Ltx. The infants had a median age at transplantation of 7 months (range 0.3-20.0 months). The underlying diagnoses were biliary atresia (n = 17), acute liver failure (n = 4), metabolic disease (n = 4). All children received CsA microemulsion (Neoral, initial 10 mg/kg/day), prednisolone, and two single doses of basiliximab as immunosuppressive drugs. The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p <0.05). This analysis demonstrates that there is a good enteral absorption of CsA in very small children post-Ltx in the early post-operative period. Based on the C(2) levels achieved, we conclude that there is a good correlation between C(0) and C(2) levels even in very small infants.
AB - Pharmacokinetic studies in adult and pediatric liver transplant recipients have shown that the C(2) monitoring is superior to the traditional determination of CsA trough levels (C(0)) as an estimate of CsA exposure. However, target reference values for C(2) in very small infants have not been established yet. The objective of our study was to assess the distribution of C(2) levels in the first week following Ltx and to analyze enteral absorption of CsA for this group of patients. We documented CsA C(0) and C(2) levels in 25 infants with a body weight below 10 kg (median 6.8 kg; range 3.0-9.8 kg) in the first 7 days after Ltx. The infants had a median age at transplantation of 7 months (range 0.3-20.0 months). The underlying diagnoses were biliary atresia (n = 17), acute liver failure (n = 4), metabolic disease (n = 4). All children received CsA microemulsion (Neoral, initial 10 mg/kg/day), prednisolone, and two single doses of basiliximab as immunosuppressive drugs. The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p <0.05). This analysis demonstrates that there is a good enteral absorption of CsA in very small children post-Ltx in the early post-operative period. Based on the C(2) levels achieved, we conclude that there is a good correlation between C(0) and C(2) levels even in very small infants.
KW - Administration, Oral
KW - Antibodies, Monoclonal/therapeutic use
KW - Basiliximab
KW - Biliary Atresia/surgery
KW - Body Weight
KW - Cyclosporine/administration & dosage
KW - Drug Monitoring
KW - Follow-Up Studies
KW - Graft Rejection/prevention & control
KW - Graft Survival
KW - Humans
KW - Immunosuppressive Agents/administration & dosage
KW - Infant
KW - Intestinal Absorption
KW - Liver Failure, Acute/surgery
KW - Liver Transplantation
KW - Metabolic Diseases/surgery
KW - Prednisolone/therapeutic use
KW - Prospective Studies
KW - Recombinant Fusion Proteins/therapeutic use
U2 - 10.1046/j.1399-3046.2003.00138.x
DO - 10.1046/j.1399-3046.2003.00138.x
M3 - SCORING: Journal article
C2 - 15049800
VL - 8
SP - 185
EP - 188
JO - PEDIATR TRANSPLANT
JF - PEDIATR TRANSPLANT
SN - 1397-3142
IS - 2
M1 - 2
ER -
